Synthesis and functional studies of self-adjuvanting multicomponent anti-HER2 cancer vaccines
Open Access
- 8 October 2021
- journal article
- research article
- Published by Royal Society of Chemistry (RSC) in RSC Advances
- Vol. 11 (53) , 33814-33822
Abstract
Breast cancer is the leading cause of cancer-related deaths among women worldwide. Human epidermal growth factor receptor 2 (HER2) overexpression is significantly associated with higher breast tumor proliferation rates. MFCH401, a 9-mer specific peptide fragment (DTILWKDIF) in the extracellular domain of the HER2 protein, is an attractive epitope for developing anti-HER2 cancer vaccines. However, the inherent low immunogenicity of MFCH401 limits its application. Herein, to induce a stronger and more durable immune response, a self-adjuvanting MFCH401-conjugated multiple-component anti-HER2 cancer vaccine was designed and synthesized by incorporating MFCH401 with lipopeptide Pam3CSK4 and a helper T cell epitope derived from tetanus toxoid P2 via an iterative condensation reaction. In vivo immunological evaluation demonstrated that the tricomponent anti-HER2 vaccine induced stronger humoral and cellular immune responses than the two-component conjugates. In addition, the induced antibodies effectively bound to HER2-overexpressing human BT474 cells. Our data clearly indicated that the MFCH401-based tricomponent anti-HER2 cancer vaccine could effectively enhance the immunogenicity of MFCH401. Structure–activity relationship analysis demonstrated that Pam3CSK4 confers better immunostimulatory activity than the helper T cell epitope P2 when conjugated with MFCH401.Keywords
This publication has 28 references indexed in Scilit:
- Active Immunotherapy of CancerImmunological Investigations, 2015
- Adjuvant HER2/Neu Peptide Cancer Vaccines in Breast CancerImmunotherapy, 2015
- Synthetic self-adjuvanting glycopeptide cancer vaccinesFrontiers in Chemistry, 2015
- Synthetic Multivalent Glycopeptide‐Lipopeptide Antitumor Vaccines: Impact of the Cluster Effect on the Killing of Tumor CellsAngewandte Chemie International Edition, 2014
- Self‐Adjuvanting Synthetic Antitumor Vaccines from MUC1 Glycopeptides Conjugated to T‐Cell Epitopes from Tetanus ToxoidAngewandte Chemie International Edition, 2013
- Immunostimulation by Synthetic Lipopeptide-Based Vaccine Candidates: Structure-Activity RelationshipsFrontiers in Immunology, 2013
- Fully Synthetic Self‐Adjuvanting Thioether‐Conjugated Glycopeptide-Lipopeptide Antitumor Vaccines for the Induction of Complement‐Dependent Cytotoxicity against Tumor CellsChemistry – A European Journal, 2012
- Effects of adjuvants on IgG subclasses elicited by virus-like ParticlesJournal of Translational Medicine, 2012
- Self‐Adjuvanting Multicomponent Cancer Vaccine Candidates Combining Per‐Glycosylated MUC1 Glycopeptides and the Toll‐like Receptor 2 Agonist Pam3CysSerAngewandte Chemie International Edition, 2011
- Robust immune responses elicited by a fully synthetic three-component vaccineNature Chemical Biology, 2007